WASHINGTON — In his first State of the Union speech, President Donald Trump renewed his pledge to reduce prescription drug prices, days after a former big pharma executive was sworn in as Secretary of Health and Human Services. Trump had stunned the pharmaceutical industry during his 2016 campaign by declaring that drug manufacturers were “getting
WASHINGTON — Former Eli Lilly and Co. executive Alex Azar has been confirmed by the Senate as the new secretary of the U.S. Department of Health & Human Services (HHS). Nominated for the HHS secretary post in November by President Donald Trump, Azar was approved by the Senate on Wednesday in a 55-43 vote, mainly
WASHINGTON — Alex Azar, a former pharmaceutical executive named by President Trump to be the next Health and Human Services secretary, told senators at a full committee nomination hearing that making prescription drugs more affordable would be one of his top priorities. “Drug prices are too high,” Azar said to the Senate health committee at
WASHINGTON — Biopharmaceutical industry executive Alex Azar has been nominated as secretary of the U.S. Department of Health and Human Services (HHS) to fill the post vacated by Tom Price. Azar is currently founder and chairman of Seraphim Strategies LLC, an Indianapolis-based consultancy focused on the biopharma and health insurance industries, including biopharmaceutical sales, marketing, pricing,
